Drug intelligence / Profile preview

HT-040

Development stage: Preclinical
Lead developer: Hinge Therapeutics
Modality: Small Molecules
Administration: Oral, Injectable

Overview

HT-040 is a preclinical **novel small-molecule** antithrombin-targeting program from Hinge Therapeutics for **hemophilia and other bleeding disorders**. The program is listed in the company pipeline together with HT-020 at the screening stage and is intended for **oral and injectable** administration. Based on the stated target, HT-040 is designed to **modulate or inhibit antithrombin** to rebalance coagulation, increase thrombin generation, and improve hemostasis in disorders such as **hemophilia B** and broader hemophilia-related bleeding phenotypes.

Targets

ATIII (Antithrombin III)

Beyond the preview

Go deeper on HT-040.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT-040.

Explore the full profile